Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-09 | Dr. Keith N. G. BradleyIndependent Director | -882,00 | 12,28k | Sale to Issuer | 13,92 | 88,25k | -0,99% |
| 2026-03-11 | Mr. Harvinder Pal SinghExec. VP & President of International Business | 18,92k | 0,00 | Derivative Exercise and Retained Stock | - | 35,42k | 114,68% |
| 2026-03-10 | Mr. Harvinder Pal SinghExec. VP & President of International Business | -1,22k | 11,65k | Derivative Exercise and Sale | 9,55 - 9,61 | 35,42k | - |
| 2026-03-11 | Mr. Harvinder Pal SinghExec. VP & President of International Business | -5,44k | 52,24k | Sale to Issuer | 9,61 | 35,42k | -13,30% |
| 2026-03-10 | Mr. Robert T. DavisExec. VP & President of Tissue Technologies | -9,17k | 88,12k | Sale to Issuer | 9,55 - 9,61 | 66,39k | -12,14% |
| 2026-03-10 | Mr. Michael J. McBreenChief Commercial Officer | -9,60k | 92,12k | Sale to Issuer | 9,55 - 9,61 | 60,74k | -13,65% |
| 2026-03-10 | Mr. Jeffrey A. MosebrookSenior VP of Finance & Principal Accounting Officer | -1,15k | 11,00k | Sale to Issuer | 9,55 - 9,61 | 35,45k | -3,13% |
| 2026-03-11 | Ms. Lea Daniels KnightExec. VP & CFO | -8,09k | 77,74k | Sale to Issuer | 9,61 | 50,49k | -13,81% |
| 2026-03-11 | Ms. Chantal Veillon-BertelootExec. VP & Chief HR Officer | -5,42k | 52,09k | Sale to Issuer | 9,61 | 22,23k | -19,60% |
| 2026-01-06 | Ms. Mojdeh PoulInsider | -1,39k | 18,25k | Derivative Exercise and Sale | 13,13 | 0,00 | - |
| 2025-11-05 | Dr. Jeffrey Alan GravesIndependent Director | 9,00k | 102,15k | Kauf | 11,35 | 41,09k | 28,05% |
| 2025-10-12 | Mr. Harvinder Pal SinghExec. VP & President of International Business | 8,68k | 0,00 | Derivative Exercise and Retained Stock | - | 21,94k | 65,53% |
| 2025-10-12 | Mr. Harvinder Pal SinghExec. VP & President of International Business | -3,28k | 43,77k | Derivative Exercise and Sale | 13,34 | 21,94k | - |
| 2025-09-01 | Ms. Chantal Veillon-BertelootExec. VP & Chief HR Officer | -3,55k | 53,73k | Sale to Issuer | 15,13 | 27,65k | -11,38% |
| 2025-08-14 | Dr. Stuart M. EssigCEO, President & Chairman | -200,00k | 2,72M | Other Disposition | 13,62 | 1,79M | -10,07% |
| 2025-07-03 | Ms. Lea Daniels KnightExec. VP & CFO | -2,56k | 34,55k | Sale to Issuer | 13,49 | 58,58k | -4,19% |
| 2025-07-03 | Mr. Jeffrey A. MosebrookSenior VP of Finance & Principal Accounting Officer | -3,35k | 45,12k | Sale to Issuer | 13,49 | 36,60k | -8,37% |
| 2025-07-01 | Mr. Jeffrey A. MosebrookSenior VP of Finance & Principal Accounting Officer | -937,00 | 12,42k | Sale to Issuer | 13,25 | 39,95k | -2,29% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
